| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:1398-1402.)
© 1997 American Heart Association, Inc.
Articles |
Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation
A Four-Year Randomized Trial
From the Department of Cardiac Surgery (K.W.), Munich- Bogenhausen; Department of Cardiac Surgery (B.M., B.R.), University Hospital, Munich-Grosshadern; Institute of Clinical Chemistry (J.T., D.N., D.S.), Medical Statistics, University Hospital, Munich-Grosshadern; and Department of Medicine I (W. von S., G.S.), University Hospital, Munich-Grosshadern, Germany.
Correspondence to Dr K. Wenke, Department of Cardiac Surgery, Munich-Bogenhausen, D-81925 Munich, Germany.
Background Accelerated graft vessel disease (GVD) represents the most serious long-term complication of heart transplantation. A possible cause underlying this progressive coronary vascular disease is believed to be post-transplantation hypercholesterolemia.
Methods and Results In a 4-year prospective randomized study with heart transplant recipients, the efficacy of primary antihypercholesterolemic therapy with simvastatin was compared with that of general dietary therapy. The aim of the treatment was to maintain post-transplantation LDL-cholesterol levels at <120 mg/dL. Seventy-two heart transplant recipients receiving standard triple immunosuppression were randomly assigned to an active-treatment group (low-cholesterol diet and simvastatin, n=35) or a control group (general dietary measures, n=37). In the course of 4 years after transplantation, the simvastatin group had significantly lower LDL-cholesterol concentrations than the control group (mean±SD, 115±14 versus 156±17 mg/dL, P=.002), a significantly better long-term survival (88.6% versus 70.3%, P=.05), and a lower incidence of GVD in the coronary angiographic findings (16.6% versus 42.3%, P=.045). The incidence of graft rejections did not differ between the two groups, although there was a tendency toward a lower number of serious rejections in the simvastatin group (2.8% versus 13.5%, P=.1). Intracoronary ultrasound performed after 4 years in a subgroup of 27 patients (simvastatin, 10; control, 17) showed less intimal thickening in patients with LDL-cholesterol levels of <110 mg/dL (170±84 versus 370±171 µm, P=.04) and a lower intimal index (13.8±7.1% versus 27.9±12.1%, P=.04).
Conclusions In comparison with dietary measures alone, the combination of a low-cholesterol diet and simvastatin after heart transplantation led to a significant reduction in cholesterol levels, a significantly higher long-term survival rate, and a lower incidence of GVD.
Key Words: simvastatin • hypercholesterolemia • transplantation • graft vessel disease
This article has been cited by other articles:
 |
|
 |
|
  K. I. Paraskevas Applications of statins in cardiothoracic surgery: more than just lipid-lowering Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Mudge Jr Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"? Circulation, December 4, 2007; 116(23): 2666 - 2668. [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. S. Packard, S. Schlegel, D. Senouf, F. Burger, P. Sigaud, T. Perneger, C.-A. Siegrist, and F. Mach Atorvastatin Treatment and Vaccination Efficacy J. Clin. Pharmacol., August 1, 2007; 47(8): 1022 - 1027. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Burton, I. Burton, and G. J Pearson Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient Ann. Pharmacother., January 1, 2007; 41(1): 133 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, K. Tanaka, B. Oeser, J. A. Kobashigawa, and J. M. Tobis Vascular remodelling after cardiac transplantation: a 3-year serial intravascular ultrasound study Eur. Heart J., July 2, 2006; 27(14): 1671 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, K. Tanaka, H. Anzai, B. Oeser, D. Lai, J. A. Kobashigawa, and J. M. Tobis Influence of Pre-Existing Donor Atherosclerosis on the Development of Cardiac Allograft Vasculopathy and Outcomes in Heart Transplant Recipients J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 V. M. Campese, M. K. Nadim, and M. Epstein Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lindenfeld, R. L. Page II, R. Zolty, S. F. Shakar, M. Levi, B. Lowes, E. E. Wolfel, and G. G. Miller Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems Circulation, January 4, 2005; 111(1): 113 - 117. [Full Text] [PDF]
|
|
|
|
 |
|
 I B McInnes, D W McCarey, and N Sattar Do statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis, December 1, 2004; 63(12): 1535 - 1537. [Full Text] [PDF]
|
|
|
|
|
|
S. de Denus, A. Al-Jazairi, E. Loh, M. Jessup, E. J Stanek, and S. A Spinler Dyslipidemias and HMG-CoA Reductase Inhibitor Prescription in Heart Transplant Recipients Ann. Pharmacother., July 1, 2004; 38(7): 1136 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Davignon Beneficial Cardiovascular Pleiotropic Effects of Statins Circulation, June 15, 2004; 109(23_suppl_1): III-39 - III-43. [Abstract] [Full Text]
|
|
|
|
|
|
F. Mach Statins as Immunomodulatory Agents Circulation, June 1, 2004; 109(21_suppl_1): II-15 - II-17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-N. Trochu, S. Mital, X.-p. Zhang, X. Xu, M. Ochoa, J. K Liao, F. A Recchia, and T. H Hintze Preservation of NO production by statins in the treatment of heart failure Cardiovasc Res, November 1, 2003; 60(2): 250 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimizu, M. Aikawa, K. Takayama, P. Libby, and R. N. Mitchell Direct Anti-Inflammatory Mechanisms Contribute to Attenuation of Experimental Allograft Arteriosclerosis by Statins Circulation, October 28, 2003; 108(17): 2113 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pierre-Paul and V. Gahtan Noncholesterol-Lowering Effects of Statins Vascular and Endovascular Surgery, September 1, 2003; 37(5): 301 - 313. [Abstract] [PDF]
|
|
|
|
|
|
F. Mulhaupt, C. M Matter, B. R Kwak, G. Pelli, N. R Veillard, F. Burger, P. Graber, T. F Luscher, and F. Mach Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells Cardiovasc Res, September 1, 2003; 59(3): 755 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Eisen, E. M. Tuzcu, R. Dorent, J. Kobashigawa, D. Mancini, H. A. Valantine-von Kaeppler, R. C. Starling, K. Sorensen, M. Hummel, J. M. Lind, et al. Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients N. Engl. J. Med., August 28, 2003; 349(9): 847 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hognestad, K. Endresen, R. Wergeland, O. Stokke, O. Geiran, T. Holm, S. Simonsen, J. K. Kjekshus, and A. K. Andreassen Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients J. Am. Coll. Cardiol., August 6, 2003; 42(3): 477 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mancini, S. Pinney, D. Burkhoff, J. LaManca, S. Itescu, E. Burke, N. Edwards, M. Oz, and A. R. Marks Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy Circulation, July 8, 2003; 108(1): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vassalli, A. Gallino, M. Weis, W. von Scheidt, L. Kappenberger, L.K. von Segesser, J.-J. Goy, and on behalf of the Working Group Microcirculation of Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy Eur. Heart J., July 1, 2003; 24(13): 1180 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Johnson, A. T. Iacono, A. Zeevi, K. R. McCurry, and S. R. Duncan Statin Use Is Associated with Improved Function and Survival of Lung Allografts Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1271 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Thompson, P. Clarkson, and R. H. Karas Statin-Associated Myopathy JAMA, April 2, 2003; 289(13): 1681 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and D. X.-M. Zhao Allograft Arteriosclerosis and Immune-Driven Angiogenesis Circulation, March 11, 2003; 107(9): 1237 - 1239. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein Risk for Myopathy With Statin Therapy in High-Risk Patients Arch Intern Med, March 10, 2003; 163(5): 553 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]
|
|
|
|
|
|
K. Wenke, B. Meiser, J. Thiery, D. Nagel, W. von Scheidt, K. Krobot, G. Steinbeck, D. Seidel, and B. Reichart Simvastatin Initiated Early After Heart Transplantation: 8-Year Prospective Experience Circulation, January 7, 2003; 107(1): 93 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Bethea, D. D. Yuh, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1427 - 1460. [Full Text]
|
|
|
|
 |
|
 F. Mach Toward a Role for Statins in Immunomodulation Mol. Interv., December 1, 2002; 2(8): 478 - 480. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. C. Fang, S. Kinlay, D. Behrendt, H. Hikita, J. L. Witztum, A. P. Selwyn, and P. Ganz Circulating Autoantibodies to Oxidized LDL Correlate With Impaired Coronary Endothelial Function After Cardiac Transplantation Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2044 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Mehra, P. A. Uber, K. Vivekananthan, S. Solis, R. L. Scott, M. H. Park, R. V. Milani, and C. J. Lavie Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1609 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Palinski and C. Napoli Unraveling Pleiotropic Effects of Statins on Plaque Rupture Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1745 - 1750. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Elisaf and D. P. Mikhailidis Statins and Renal Function Angiology, September 1, 2002; 53(5): 493 - 502. [Abstract] [PDF]
|
|
|
|
|
|
W. Palinski and S. Tsimikas Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1673 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pascual, T. Theruvath, T. Kawai, N. Tolkoff-Rubin, and A. B. Cosimi Strategies to Improve Long-Term Outcomes after Renal Transplantation N. Engl. J. Med., February 21, 2002; 346(8): 580 - 590. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Massy and C. Guijarro Statins: effects beyond cholesterol lowering Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1738 - 1741. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Kapadia, S. E. Nissen, K. M. Ziada, G. Rincon, T. D. Crowe, N. Boparai, J. B. Young, and E. M. Tuzcu Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study J. Am. Coll. Cardiol., July 1, 2001; 38(1): 206 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Valantine, P. Rickenbacker, M. Kemna, S. Hunt, Y.-D. I. Chen, G. Reaven, and E. B. Stinson Metabolic Abnormalities Characteristic of Dysmetabolic Syndrome Predict the Development of Transplant Coronary Artery Disease : A Prospective Study Circulation, May 1, 2001; 103(17): 2144 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M Lefer, R. Scalia, and D. J Lefer Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease Cardiovasc Res, February 1, 2001; 49(2): 281 - 287. [Full Text] [PDF]
|
|
|
|
|
|
W. Palinsk New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Sparrow, C. A. Burton, M. Hernandez, S. Mundt, H. Hassing, S. Patel, R. Rosa, A. Hermanowski-Vosatka, P.-R. Wang, D. Zhang, et al. Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Aranda Jr. and J. Hill Cardiac Transplant Vasculopathy Chest, December 1, 2000; 118(6): 1792 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Pethig, V Klauss, B Heublein, H Mudra, A Westphal, C Weber, K Theisen, and A Haverich Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors Heart, November 1, 2000; 84(5): 494 - 498. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Ward, G. Pasterkamp, A. C. Yeung, and C. Borst Arterial Remodeling : Mechanisms and Clinical Implications Circulation, September 5, 2000; 102(10): 1186 - 1191. [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, J. Van Cleemput, D. Collen, and J. Vanhaecke Oxidized Low Density Lipoprotein Is a Prognostic Marker of Transplant-Associated Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 698 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ansell, K. E. Watson, and A. M. Fogelman An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines JAMA, December 1, 1999; 282(21): 2051 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lindelow, C.-H. Bergh, C. Lamm, B. Andersson, and F. Waagstein Graft coronary artery disease is strongly related to the aetiology of heart failure and cellular rejections Eur. Heart J., September 2, 1999; 20(18): 1326 - 1334. [Abstract] [PDF]
|
|
|
|
 |
|
 U. Laufs, D. Marra, K. Node, and J. K. Liao 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27Kip1 J. Biol. Chem., July 30, 1999; 274(31): 21926 - 21931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pethig, B. Heublein, R. R. Meliss, and A. Haverich Volumetric remodeling of the proximal left coronary artery: Early versus late after heart transplantation J. Am. Coll. Cardiol., July 1, 1999; 34(1): 197 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Holschermann, R. M. Bohle, H. Zeller, H. Schmidt, U. Stahl, L. Fink, H. Grimm, H. Tillmanns, and W. Haberbosch In Situ Detection of Tissue Factor within the Coronary Intima in Rat Cardiac Allograft Vasculopathy Am. J. Pathol., January 1, 1999; 154(1): 211 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Jain, S. R. Ramee, C. J. White, M. R. Mehra, H. O. Ventura, S. Zhang, J. S. Jenkins, and T. J. Collins Coronary stenting in cardiac allograft vasculopathy J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1636 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Walter, J. Haendeler, J. Galle, A. M. Zeiher, and S. Dimmeler Cyclosporin A Inhibits Apoptosis of Human Endothelial Cells by Preventing Release of Cytochrome C From Mitochondria Circulation, September 22, 1998; 98(12): 1153 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Simvastatin Prolongs Survival in Heart Transplant Recipients Journal Watch Cardiology, September 23, 1997; 1997(923): 5 - 5. [Full Text]
|
|